Figure 5

WT CD4 ⁺ T cell co-transfer prevents GKO CD4 ⁺ T cell induced mortality. (A) Relative MHC I-A^d class II mRNA expression in the CNS of infected SCID recipients of WT, WT/GKO or GKO CD4⁺ T cells determined by quantitative real-time PCR. Data represent the mean ± SEM of two independent experiments with n = 4 per experiment. Microglial MHC class II expression quantified by flow cytometry in infected SCID recipients of WT, WT/GKO or GKO CD4⁺ T cells. Data represent the mean ± SD of three separate experiments with n = 4 per group per experiment. (B) Survival was assessed following infection of SCID recipients of WT (n = 20), WT/GKO (n = 20) or GKO (n = 12) CD4⁺ T cells. Data represent four separate experiments. (C) Control of virus replication analyzed by plaque assay in infected control, SCID recipients of WT, WT/GKO or GKO CD4⁺ T cells at day eight p.i. Data represent the average (±SD) of eight mice per group combined from two independent experiments. (D) Total number of bone-marrow-derived leukocytes (CD45^hi) and neutrophils (Ly6G⁺) analyzed by flow cytometry at day eight p.i. in brains of infected SCID recipients of WT, WT/GKO and GKO CD4⁺ T cells. Data represent the mean of twelve mice per group combined from three independent experiments.